3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
Specimen Handling
613
pembrolizumab
563
Magnetic Resonance Spectroscopy
536
Carboplatin
425
Cisplatin
375
Cyclophosphamide
373
Biopsy
357
Paclitaxel
306
Gemcitabine
303
Nivolumab
300
Radiotherapy
260
Bevacizumab
234
Dexamethasone
209
fludarabine
205
Docetaxel
187
durvalumab
182
atezolizumab
173
Oxaliplatin
172
venetoclax
168
Fluorouracil
166
Rituximab
165
Pemetrexed
163
Capecitabine
158
Doxorubicin
157
Radiation
155
Radiosurgery
148
Etoposide
137
Leucovorin
133
Ipilimumab
133
Lenalidomide
131
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
bexmarilimab
×
90 days
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled